Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR Therapy with Nivolumab in Advanced Solid Tumors
NCT02775292Phase 1Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jan 2017
- Primary completion
- Apr 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of letetresgene autoleucel in Solid neoplasm, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Incidence of adverse events up to 15 years and Maximum tolerated dose. Started Jan 2017; status: completed.
02
Drugs
letetresgene autoleucel
03
Conditions
Solid neoplasm
Beyond the preview
Go deeper on NCT02775292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02775292.